SOURCE: TriMarkPublications.com

TriMarkPublications.com

August 14, 2013 13:45 ET

Global Biologic Drugs Market to Jump to Over $220 Billion by 2019

NEW YORK, NY--(Marketwired - Aug 14, 2013) - TriMarkPublications.com cites in its newly published "Biologics and Biosimilars World Markets" report that the global biologic drugs market will jump to over $220 billion by 2019. For more information, visit: http://www.trimarkpublications.com/biologics-and-biosimilars-world-markets/.

Biologics, also known as biopharmaceuticals, can be categorized into three main modalities: therapeutic proteins, monoclonal antibodies and vaccines. Most of the biologic drugs marketed so far are recombinant therapeutic protein drugs, which are used to relieve patients suffering from chronic diseases, such as cancer, diabetes, cardiovascular diseases, infertility and cystic fibrosis. Globally, the U.S. commands 43% of biologics sales, followed by the E.U. (21%) and Japan (9%).

The "Biologics and Biosimilars World Markets" report covers key biologic and biosimilar drugs, including:

  • Humira (Adalimumab)
  • Remicade (Infliximab)
  • Lantus (Insulin Glargine)
  • Levemir (Insulin Detemir)
  • Privigen (Immune Globulin Intravenous)
  • Perjeta (Pertuzumab)
  • Soliris (Eculizumab)
  • Eylea (Aflibercept)
  • Revlimid (Lenalidomide)
  • Herceptin (Trastuzumab)
  • Gardasil
  • Varivax (Varicella Virus Vaccine Live)
  • Gammagard Liquid (Immune Globulin Infusion (Human))
  • Aranesp (Darbepoetin Alfa)
  • Enbrel (Etanercept)
  • Epogen/Procrit/Eprex/Erypo (Epoetin Alfa)
  • Genotropin (Somatropin)
  • Herceptin (Trastuzumab)
  • Humira (Adalimumab)
  • Neulasta (Pegfilgrastim)
  • Neupogen (Filgrastim)
  • Remicade (Infliximab)
  • Rituxan/MabThera (Rituximab)

The "Biologics and Biosimilars World Markets" report examines companies manufacturing biologic and biosimilar equipment and supplies in the world. Companies covered include: 3Bio, Abbott, AbbVie, Actelion, Amgen, Amoytop, Anhui Anke, Apotex, Astellas, AstraZeneca, Bayer, Beijing Four Rings, Bharat Serums and Vaccines, Biocon, Biogen Idec, Bioton, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cipla, Dr. Reddy's, Elan, Eli Lilly, Gideon Richter, Gilead Sciences, GlaxoSmithKline, Hospira, Intas, Johnson & Johnson, Merck, Mylan, Novartis, Pfizer, Roche, Sandoz, Sanofi, Stada Arzneimittel Aktiengesellschaft, Teva and Watson.

Detailed charts with sales forecasts and marketshare data are included. For more information, visit: http://www.trimarkpublications.com/biologics-and-biosimilars-world-markets/.

About TriMarkPublications.com

TriMarkPublications.com is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit http://www.trimarkpublications.com.

Important Notice

The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.

Contact Information